Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.